Pro Dex vs AVITA Medical
PDEX and RCEL side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How PDEX and RCEL compare
AVITA Medical is the larger company, worth 2.3 times as much as Pro Dex ($501M against $216M).
AVITA Medical grew revenue faster over the last twelve months (17.0% versus 13.3% for Pro Dex).
Pro Dex keeps more of each dollar of sales as profit, with a net margin of 15.1% compared with −42.7% at AVITA Medical.
Pro Dex scores higher on the StockData Score (18 against 5 for AVITA Medical), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | PDEX | RCEL |
|---|---|---|
| Size and price | ||
| Market cap | $216M | $501M |
| Share price | $67.42 | $16.20 |
| Change, 1 year | 101% | 309% |
| Change, 5 years | 230% | 8.1% |
| Beta (5Y) | 0.26 | 1.96 |
| Employees | 181 | 226 |
| StockData Score | ||
| Total score | 18 (better) | 5 |
| Valuation score | 2 (better) | 0 |
| Growth score | 4 (better) | 3 |
| Performance score | 6 (better) | 1 |
| Health score | 6 (better) | 1 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/E | 18.6× | – |
| P/S | 2.7× (better) | 5.9× |
| P/B | 4.4× | – |
| EV/EBITDA | 14.4× | – |
| P/FCF | 20.2× | – |
| PEG | 0.66 | – |
| FCF yield | 5.0% (better) | −3.8% |
| Fair value | $70.38 | – |
| Margin of safety | 4.2% | – |
| Growth | ||
| Revenue growth (TTM) | 13.3% | 17.0% (better) |
| Revenue growth, 5Y average | 15.3% | 67.2% (better) |
| Net income growth (TTM) | 7.5% | – |
| EPS growth (TTM) | 8.4% | – |
| EPS growth, 5Y average | 21.3% | – |
| Profitability | ||
| Gross margin | 32.5% | 82.4% (better) |
| Operating margin | 16.8% (better) | −33.9% |
| Net margin | 15.1% (better) | −42.7% |
| FCF margin | 13.4% (better) | −22.8% |
| Return on equity | 26.5% | – |
| Return on invested capital | 24.1% (better) | −276% |
| Financial health | ||
| Debt / equity | 0.25 | – |
| Net debt / EBITDA | −0.05 | – |
| Interest coverage | 15.4× (better) | −5.1× |
| Current ratio | 4.19 (better) | 1.20 |
| Altman Z-score | 7.91 (better) | −9.18 |
| Piotroski F-score | 6 (better) | 3 |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 22.9% | 15.9% |
| Held by insiders | 45.7% | 2.7% |
| Insider net buying, 12 months | −$2.0M | $235K (better) |
| Superinvestors holding | 1 | – |
| Short interest, % of float | 15.6% | – |
Go deeper
- PDEX stock overview
- PDEX income statement
- PDEX valuation and score
- RCEL stock overview
- RCEL income statement
- RCEL valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.